Please ensure Javascript is enabled for purposes of website accessibility

Parkinson named to Zyngenia’s board of directors

David Parkinson, M.D., has been appointed to the board of directors of Zyngenia Inc., a Gaithersburg-based biopharmaceutical company, and named head of its clinical advisory board. He will also serve as interim chief medical officer.

From 2007 until 2012, Parkinson served as president and CEO of Nodality, a South San Francisco-based venture-financed biotech company. Before that he was senior vice president, oncology R&D, at Biogen Idec, and his resume also includes stints with Amgen and Novartis. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as chief of the Investigational Drug Branch, then as acting associate director of the Cancer Therapy Evaluation Program. He has held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine.

Parkinson received his M.D. as gold medalist from the University of Toronto Faculty of Medicine in 1977 and trained at McGill University and New England Medical Center. He is a past chairman of the Food & Drug Administration Biologics Advisory Committee, past president of the International Society of Biological Therapy, and past editor of the Journal of Immunotherapy. He recently completed terms as a member of the FDA’s Science Board, the board of directors of the American Association of Cancer Research and the National Cancer Policy Forum of the Institute of Medicine.